Vir Biotechnology shares are trading lower after the company's Phase 2 PENINSULA trial of VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology's shares have dropped following the failure of its Phase 2 PENINSULA trial of VIR-2482, aimed at preventing symptomatic influenza A illness, to meet primary or secondary efficacy endpoints.
July 20, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology's stock price is expected to decrease in the short term due to the failure of its Phase 2 PENINSULA trial of VIR-2482.
The failure of a clinical trial often leads to a decrease in the stock price of a biotech company. In this case, Vir Biotechnology's Phase 2 PENINSULA trial of VIR-2482 did not meet its primary or secondary efficacy endpoints, which is likely to negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100